Today, Alzheimer's research isn't limited to just a few possibilities. University researchers and pharmaceutical companies large and small are exploring a range of treatment opportunities. Antidote caught up with Keith W. Whitaker, PhD, Director of Scientific Programs, Neuroscience, at the BrightFocus Foundation for his take on the latest – and why clinical trial participation is so critical to the process.
The information provided in this section is a public service of BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.